On March 26, 2026, Upstream Bio, Inc. entered into a Sales Agreement with Leerink Partners LLC to offer and sell up to $150 million of common stock through an at-the-market offering on Nasdaq. The Agent receives a commission of up to 3.0% of gross proceeds, with customary indemnification rights.
Key takeaways
Entered Sales Agreement with Leerink Partners LLC on March 26, 2026
ATM Offering for up to $150,000,000 aggregate sales price of common stock ($0.001 par value)
Sales through Agent using commercially reasonable efforts on Nasdaq
Agent commission up to 3.0% of gross proceeds
Filed Prospectus Supplement on March 26, 2026 under S-3ASR (File No. 333-291267)